Analysts Offer Insights on Healthcare Companies: Pieris Pharmaceuticals (NASDAQ: PIRS) and Nektar Therapeutics (NASDAQ: NKTR)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pieris Pharmaceuticals (PIRSResearch Report) and Nektar Therapeutics (NKTRResearch Report) with bullish sentiments.

Pieris Pharmaceuticals (PIRS)

William Blair analyst Matt Phipps maintained a Buy rating on Pieris Pharmaceuticals today. The company’s shares closed last Monday at $3.95.

According to TipRanks.com, Phipps ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -14.7% and a 34.1% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Atara Biotherapeutics, and Autolus Therapeutics.

Currently, the analyst consensus on Pieris Pharmaceuticals is a Strong Buy with an average price target of $7.00, a 72.8% upside from current levels. In a report issued on November 5, H.C. Wainwright also maintained a Buy rating on the stock with a $7.00 price target.

See today’s analyst top recommended stocks >>

Nektar Therapeutics (NKTR)

In a report released today, Andy Hsieh from William Blair maintained a Buy rating on Nektar Therapeutics. The company’s shares closed last Monday at $20.98.

According to TipRanks.com, Hsieh is ranked #1269 out of 5642 analysts.

Currently, the analyst consensus on Nektar Therapeutics is a Moderate Buy with an average price target of $27.33, which is a 24.2% upside from current levels. In a report issued on November 7, Piper Jaffray also maintained a Buy rating on the stock with a $35.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.